综述

乙型肝炎肝硬化患者的抗病毒治疗

  • 谷雷雷 ,
  • 张欣欣
展开
  • 1.上海交通大学 医学院附属瑞金医院北院消化科, 上海 201801; 2.上海交通大学 医学院附属瑞金医院、瑞金北院感染科, 上海 200025
谷雷雷(1982—), 男, 住院医师, 博士; 电子信箱: ray01982@163.com。

网络出版日期: 2016-01-13

基金资助

国家自然科学基金(81371860)

Antiviral therapy in patients with hepatitis B virus-related liver cirrhosis

  • GU Lei-lei ,
  • ZHANG Xin-xin
Expand
  • 1.Department of Gastroenterology, Ruijin Hospital North, Shanghai Jiao Tong University School of Medicine, Shanghai 201801, China; 2.Department of Infectious Diseases, Ruijin Hospital, Ruijin Hospital North, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China

Online published: 2016-01-13

Supported by

National Natural Science Foundation of China, 81371860

摘要

慢性乙型肝炎病毒感染是肝硬化的主要病因之一。肝硬化的进展与体内乙肝病毒DNA水平相关,抗病毒治疗能够抑制病毒复制,减少肝硬化并发症的发生,改善肝硬化患者的生存率。所以在乙肝肝硬化的治疗中,提供有效的抗病毒治疗是非常重要的措施。现有的抗病毒药物包括核苷(酸)类似物(Nuc)与α干扰素。该文简要介绍了抗病毒药物在乙肝肝硬化患者当中使用的情况,特别突出了指南对乙肝肝硬化的推荐意见。

本文引用格式

谷雷雷 , 张欣欣 . 乙型肝炎肝硬化患者的抗病毒治疗[J]. 上海交通大学学报(医学版), 2015 , 35(11) : 1717 . DOI: 10.3969/j.issn.1674-8115.2015.11.024

Abstract

Chronic hepatitis B virus (HBV) infection is one of the major causes of liver cirrhosis. The progression of cirrhosis is associated with the HBV DNA level. The antiviral therapy can inhibit the viral replication, reduce complications of cirrhosis, and improve the survival rate of patients with cirrhosis. It is important to provide effective antiviral therapy for the treatment of HBV-related liver cirrhosis. Currently, antiviral drugs include nucleos(t)ide analogues (Nucs) and IFNα. This paper briefly introduces the application of these antiviral drugs to patients with cirrhosis and particularly highlights the recommendations in native and foreign practice guidelines for the treatment of HBV-related liver cirrhosis.

文章导航

/